Core Insights - COEPTIS, Inc. successfully closed an additional 10 million, indicating strong investor confidence in the company's innovative therapeutic solutions and technology-driven growth [1][2][3] Financing Details - The financing round was led by CJC Investment Trust, controlled by board member Christopher Calise, who increased their initial investment [2] - The Series A Preferred shares are convertible into common stock at a price of $8.00 per share, with investors receiving a 15% equity interest in newly formed subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics Inc. [2] Use of Proceeds - The funds will be used to strengthen the company's balance sheet, repay obligations, and support general corporate purposes, alongside enhancing operational capabilities through AI-driven tools from the NexGenAI Affiliates Network platform [3][4] - The additional capital will accelerate the integration of advanced AI solutions and automation capabilities, improving research processes and overall operational efficiency [3] Company Strategy - COEPTIS aims to drive innovation in technology and AI while fostering a culture of responsible innovation to create a self-sustaining business model for long-term success and profitability [4] - The company is focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, with a therapeutic portfolio that includes assets licensed from Deverra Therapeutics [5][6] Technology Division - A newly established Technology Division will enhance operational capabilities through advanced technologies, including AI-powered marketing software and robotic process automation tools [6]
COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration